COMMUNIQUÉS West-GlobeNewswire

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
30/04/2024
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, [...]
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
30/04/2024
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will [...]
Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
30/04/2024
BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today [...]
CDR-Life Announces Fourth Milestone Achievement with Boehringer Ingelheim in Phase 1 Geographic Atrophy Trial
30/04/2024
ZÜRICH, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the advancement of the Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim (BI) for the [...]
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30/04/2024
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement [...]
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30/04/2024
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira ® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement [...]
EAACI Congress 2024: Innovation and Advances in Allergy Treatment
30/04/2024
Over 150 scientific sessions will be presented during the congress, focusing on advancements in environmental science, food allergies, innovations in immunotherapy, and pediatric allergies, among others. Precision [...]
Congrès EAACI 2024 : innovations et progrès dans le traitement des allergies
30/04/2024
Lors de ce congrès, plus de 150 sessions scientifiques seront présentées. Les sujets abordés se concentreront sur les progrès de la science environnementale, les allergies alimentaires, les innovations en matière d' [...]
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
30/04/2024
Oslo, Norway, 30 April 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 23 May 2024 at 13:00 CEST. A physical Annual General Meeting will [...]
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
30/04/2024
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors Co-Founder of Spark Therapeutics with over 20 years of industry experience to support ViaNautis Bio in its next stage of development [...]
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30/04/2024
Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on [...]
BioSenic S.A. : Information on the total number of voting rights and shares
30/04/2024
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and [...]
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
30/04/2024
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 30 avril 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto [...]
Combined General Meeting of May 22, 2024 - Availability of preparatory documents
30/04/2024
Press Release Paris – April 30, 2024 – EUROAPI’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 22, 2024 at 10:00 a.m. (CET) at the Centre de Conférences Verso, 52 rue de la [...]
Assemblée Générale mixte du 22 mai 2024 - Modalités de mise à disposition ou de consultation des documents préparatoires
30/04/2024
Communiqué de presse Paris – Le 30 avril 2024 – Les actionnaires d’EUROAPI sont invités à participer à l’Assemblée Générale mixte qui se tiendra le mercredi 22 mai 2024 à 10h00 au Centre de Conférences Verso, 52 rue de [...]
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
30/04/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of [...]
Stride Autism Centers Hosts Open House in Downers Grove, IL
30/04/2024
DOWNERS GROVE, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Stride Autism Centers (“Stride”) is thrilled to announce the grand opening of its newest center in Downers Grove, IL. Committed to becoming an integral part of the [...]
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
30/04/2024
FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global [...]
Hydreight Achieves Record Revenue, Files Audited Financial Statements for Fiscal Year 2023
30/04/2024
2023 Adjusted Revenue 1 record revenue of $17.05 million, an increase of 102% compared to 2022. 2023 GAAP revenue was $11.51 million an increase of 170% compared to 2022. 2023 gross margin of 43.11% compared to 43.00% [...]

Pages